Valeant's Study Results Disappoint
Disappointing late stage test results for Valeant Pharmaceuticals International's (VRX) hepatitis C treatment Viramidine sent the stock price plummeting $2.65 to close at $16.03.
posted by FC Market News at 9:31 AM
0 Comments:
Post a Comment
<< Home